Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT)

This article has no abstract
Epistemonikos ID: 956d6af97f12600ae9d71fb9d66c4834ee14c3a6
First added on: Feb 11, 2025